Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for ytterligere informasjon, vennligst referer til seksjon 5.

Pregabalin Mylan Pharma Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

pregabalin mylan pharma

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma er indisert som tilleggsbehandling hos voksne med partielle anfall med eller uten sekundær generalisering. generell angst disorderpregabalin mylan pharma er angitt for behandling av generalisert angstlidelse (gad) i voksne.

Tramagetic OD 300 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic od 300 mg

mundipharma as - tramadolhydroklorid - depottablett - 300 mg

Tramagetic OD 150 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic od 150 mg

mundipharma as - tramadolhydroklorid - depottablett - 150 mg

Tramagetic OD 200 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic od 200 mg

mundipharma as - tramadolhydroklorid - depottablett - 200 mg

Tramagetic Retard 100 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic retard 100 mg

mundipharma as - tramadolhydroklorid - depottablett - 100 mg

Tramagetic Retard 75 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic retard 75 mg

mundipharma as - tramadolhydroklorid - depottablett - 75 mg

Tramagetic Retard 150 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic retard 150 mg

mundipharma as - tramadolhydroklorid - depottablett - 150 mg

Tramagetic Retard 200 mg Norwe - Kinorwe - Statens legemiddelverk

tramagetic retard 200 mg

mundipharma as - tramadolhydroklorid - depottablett - 200 mg

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.